[{"orgOrder":0,"company":"Liverpool School of Tropical Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dimercaprol","moa":"Heavy metal","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Liverpool School of Tropical Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Liverpool School of Tropical Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Liverpool School of Tropical Medicine \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for BAL

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Liverpool School of Tropical Medicine

                          Country arrow
                          Cophex
                          Not Confirmed

                          Liverpool School of Tropical Medicine

                          Country arrow
                          Cophex
                          Not Confirmed

                          Details : Study found dimercaprol and its derivative 2,3-dimercapto-1-propanesulfonic acid (DMPS) were found to inhibit the in vitro activity of snake venom enzymes that rely on zinc ions to function.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 05, 2020

                          Lead Product(s) : Dimercaprol

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank